JP2017523985A - 抗原用担体分子 - Google Patents

抗原用担体分子 Download PDF

Info

Publication number
JP2017523985A
JP2017523985A JP2017506294A JP2017506294A JP2017523985A JP 2017523985 A JP2017523985 A JP 2017523985A JP 2017506294 A JP2017506294 A JP 2017506294A JP 2017506294 A JP2017506294 A JP 2017506294A JP 2017523985 A JP2017523985 A JP 2017523985A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
acid sequence
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017506294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523985A5 (OSRAM
Inventor
ベルティ，フランチェスコ
コッツィ，ロベルタ
グランディ，グイド
マイオーネ，ドメニコ
イロス，イマクラーダ マルガリット
イロス，イマクラーダ マルガリット
ダニエラ リナウド，チーラ
ダニエラ リナウド，チーラ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2017523985A publication Critical patent/JP2017523985A/ja
Publication of JP2017523985A5 publication Critical patent/JP2017523985A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017506294A 2014-08-05 2015-08-05 抗原用担体分子 Pending JP2017523985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179945 2014-08-05
EP14179945.2 2014-08-05
PCT/EP2015/068012 WO2016020413A1 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Publications (2)

Publication Number Publication Date
JP2017523985A true JP2017523985A (ja) 2017-08-24
JP2017523985A5 JP2017523985A5 (OSRAM) 2018-07-19

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506294A Pending JP2017523985A (ja) 2014-08-05 2015-08-05 抗原用担体分子

Country Status (16)

Country Link
US (1) US10245310B2 (OSRAM)
EP (1) EP3177324A1 (OSRAM)
JP (1) JP2017523985A (OSRAM)
KR (1) KR20170039709A (OSRAM)
CN (1) CN108064174A (OSRAM)
AR (1) AR101455A1 (OSRAM)
AU (1) AU2015299008B2 (OSRAM)
BE (1) BE1022792B1 (OSRAM)
BR (1) BR112017002183A2 (OSRAM)
CA (1) CA2957118A1 (OSRAM)
EA (1) EA201790239A1 (OSRAM)
IL (1) IL250238A0 (OSRAM)
MX (1) MX2017001638A (OSRAM)
SG (1) SG11201700673RA (OSRAM)
WO (1) WO2016020413A1 (OSRAM)
ZA (1) ZA201700824B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527206A (ja) * 2019-04-02 2022-05-31 バックスサイト・インコーポレイテッド 侵入プラスミド抗原ｂの最適化された無細胞合成、および関連する組成物、および使用方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2878307T3 (pl) * 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
BR112019020853A2 (pt) * 2017-04-04 2020-05-12 Avidea Technologies, Inc. Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
AU2019299836B2 (en) * 2018-07-04 2025-08-21 Vaxcyte, Inc. Improvements in immunogenic conjugates
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
JP2023503086A (ja) 2019-11-22 2023-01-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌サッカリド複合糖質ワクチンの用法及び用量
WO2021250626A2 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
US20230303637A1 (en) 2020-06-12 2023-09-28 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
GB202215634D0 (en) * 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532930A (ja) * 2005-02-01 2008-08-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 連鎖球菌性莢膜糖の複合
WO2009101403A1 (en) * 2008-02-11 2009-08-20 Novartis Ag Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus
JP2013523718A (ja) * 2010-04-01 2013-06-17 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅの処置および予防のための免疫原性タンパク質および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784211A4 (en) * 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
US20090104218A1 (en) * 2004-12-22 2009-04-23 J. Craig Venter Institute Group B Streptococcus
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP2063911A2 (en) 2006-07-26 2009-06-03 Novartis Ag Immunogenic compositions for gram positive bacteria
US8465751B2 (en) * 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201114923D0 (en) * 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US20150273042A1 (en) * 2012-02-24 2015-10-01 Novartis Ag Pilus proteins and compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532930A (ja) * 2005-02-01 2008-08-21 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 連鎖球菌性莢膜糖の複合
WO2009101403A1 (en) * 2008-02-11 2009-08-20 Novartis Ag Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus
JP2013523718A (ja) * 2010-04-01 2013-06-17 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅの処置および予防のための免疫原性タンパク質および組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527206A (ja) * 2019-04-02 2022-05-31 バックスサイト・インコーポレイテッド 侵入プラスミド抗原ｂの最適化された無細胞合成、および関連する組成物、および使用方法

Also Published As

Publication number Publication date
US10245310B2 (en) 2019-04-02
BR112017002183A2 (pt) 2018-01-16
WO2016020413A1 (en) 2016-02-11
CA2957118A1 (en) 2016-02-11
EP3177324A1 (en) 2017-06-14
US20170224803A1 (en) 2017-08-10
AU2015299008A1 (en) 2017-02-23
EA201790239A1 (ru) 2017-07-31
BE1022792B1 (fr) 2016-09-06
AU2015299008B2 (en) 2018-08-02
IL250238A0 (en) 2017-03-30
CN108064174A (zh) 2018-05-22
MX2017001638A (es) 2017-04-27
SG11201700673RA (en) 2017-02-27
BE1022792A1 (fr) 2016-09-06
KR20170039709A (ko) 2017-04-11
AR101455A1 (es) 2016-12-21
ZA201700824B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
JP2017523985A (ja) 抗原用担体分子
JP6170932B2 (ja) ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
CN103209708B (zh) 免疫原性组合物
JP5781542B2 (ja) Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
JP5818826B2 (ja) 連鎖球菌性莢膜糖の複合
JP7036854B2 (ja) シクロアルキン誘導体化糖類
AU2013326584B2 (en) Nonlinear saccharide conjugates
JP5572097B2 (ja) 結合体化されたβ−１，３−結合グルカン
JP2023537945A (ja) 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
JP2016029103A (ja) 免疫原性組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191023